Mohamad Baker Berjaoui

Dec 10, 2024 | urologytimes.com | Mohamad Baker Berjaoui

In this video, Mohamad Baker Berjaoui, MD, discusses the finding from the BJUI Compass paper, “WATER versus WATER II 5-year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80-cm3 and 80–150-cm3 prostates” that Aquablation had comparable long-term outcomes for prostates of different sizes. Berjaoui is a urology resident at the University of Toronto in Ontario, Canada.

Dec 4, 2024 | urologytimes.com | Mohamad Baker Berjaoui

In this video, Mohamad Baker Berjaoui, MD, provides an overview of the BJUI Compass paper, “WATER versus WATER II 5-year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80-cm3 and 80–150-cm3 prostates.” Berjaoui is a urology resident at the University of Toronto in Ontario, Canada. Transcription:Please provide an overview of this study and its notable findings. This study basically [looks at] WATER and WATER II over 5 years' follow-up.

Sep 10, 2024 | bjui-journals.onlinelibrary.wiley.com | Mohamad Baker Berjaoui |David-Dan Nguyen |Karim Daher |Saud Almousa

1 INTRODUCTION Benign prostatic hyperplasia (BPH) is a prevalent condition among elderly men with increasing prevalence with age, affecting approximately 60% of men by the age of 65.

Jul 23, 2024 | cuaj.ca | Nick Lee |Patricia Nadeau |Mohamad Baker Berjaoui |Anis Assad

Abstract INTRODUCTION: Health-related quality of life (HRQoL) is often reduced in patients with urolithiasis. The objective of this study was to perform a systematic review to describe impact on HRQoL based on different modalities of treatment for small urolithiases with a diameter smaller or equal to 10 mm.